Latest Content

The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.

An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.

Olverembatinib produced progressively deepening cytogenetic and molecular responses in second-line chronic-phase chronic myeloid leukemia.

The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.

The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01.

MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.

Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.

Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.

The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.

The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.

The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.

R. Lor Randall, MD, FACS, discusses what’s next for TGCT treatment and the most important developments to come out of 2026 TGCT Master Workshop.

Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.

UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.

In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.

Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.

Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.

The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.

Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.

ASCO’s ctDNA guidelines support testing for genetic alterations in select scenarios but do not endorse it for residual disease or recurrence monitoring.

Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.

Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.

The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.

Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.

The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.

Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.

Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.

ctDNA clearance and MRD status may help identify which patients with resectable NSCLC get the greatest benefit from perioperative immunotherapy.

PLN-101095 earned an FDA fast track designation in combination with pembrolizumab for solid tumors resistant to immune checkpoint inhibitors.

Following the RASolute 302 readout, ESMO now endorses daraxonrasib after chemotherapy progression in RAS-mutated metastatic pancreatic cancer.

Harold P. Freeman, MD, pioneer of patient navigation and cancer disparities research, has died at 93. He spent decades bridging gaps in cancer care access.

Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.

Dana M. Chase, MD, joins Angeles Alvarez Secord, MD, MHSc, to discuss mocertatug rezetecan in gynecologic malignancies.

Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.

A study found that the vast majority of veterans with early prostate cancer pursued surveillance instead of treatment.